Interparfums Valuation
Is IPAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IPAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IPAR ($124.65) is trading above our estimate of fair value ($58.43)
Significantly Below Fair Value: IPAR is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IPAR?
Key metric: As IPAR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is IPAR's PE Ratio? | |
|---|---|
| PE Ratio | 26.5x |
| Earnings | US$150.55m |
| Market Cap | US$3.99b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3x |
| Enterprise Value/EBITDA | 15.2x |
| PEG Ratio | 3.3x |
Price to Earnings Ratio vs Peers
How does IPAR's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 41.9x | ||
COTY Coty | 39.8x | 23.3% | US$6.3b |
BRBR BellRing Brands | 42.2x | 12.3% | US$9.3b |
ODD Oddity Tech | 22.4x | 18.5% | US$2.3b |
ELF e.l.f. Beauty | 63.3x | 33.6% | US$6.8b |
IPAR Interparfums | 26.5x | 7.9% | US$4.0b |
Price-To-Earnings vs Peers: IPAR is good value based on its Price-To-Earnings Ratio (26.5x) compared to the peer average (41.9x).
Price to Earnings Ratio vs Industry
How does IPAR's PE Ratio compare vs other companies in the US Personal Products Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
NEPT.F Neptune Wellness Solutions | n/a | n/a | US$4.00 |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: IPAR is expensive based on its Price-To-Earnings Ratio (26.5x) compared to the North American Personal Products industry average (26.5x).
Price to Earnings Ratio vs Fair Ratio
What is IPAR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 26.5x |
| Fair PE Ratio | 22.9x |
Price-To-Earnings vs Fair Ratio: IPAR is expensive based on its Price-To-Earnings Ratio (26.5x) compared to the estimated Fair Price-To-Earnings Ratio (22.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$124.65 | US$140.80 +13.0% | 31.1% | US$172.00 | US$54.00 | n/a | 5 |
| Nov ’25 | US$121.69 | US$142.60 +17.2% | 31.2% | US$172.00 | US$54.00 | n/a | 5 |
| Oct ’25 | US$131.15 | US$142.60 +8.7% | 31.2% | US$172.00 | US$54.00 | n/a | 5 |
| Sep ’25 | US$128.84 | US$142.60 +10.7% | 31.2% | US$172.00 | US$54.00 | n/a | 5 |
| Aug ’25 | US$137.38 | US$141.80 +3.2% | 33.4% | US$192.00 | US$54.00 | n/a | 5 |
| Jul ’25 | US$115.24 | US$163.75 +42.1% | 12.2% | US$192.00 | US$140.00 | n/a | 4 |
| Jun ’25 | US$119.78 | US$163.75 +36.7% | 12.2% | US$192.00 | US$140.00 | n/a | 4 |
| May ’25 | US$115.64 | US$169.97 +47.0% | 9.0% | US$192.00 | US$140.00 | n/a | 6 |
| Apr ’25 | US$138.31 | US$170.63 +23.4% | 9.1% | US$192.00 | US$140.00 | n/a | 6 |
| Mar ’25 | US$145.60 | US$170.72 +17.3% | 9.0% | US$192.00 | US$140.00 | n/a | 6 |
| Feb ’25 | US$143.53 | US$170.72 +18.9% | 9.0% | US$192.00 | US$140.00 | n/a | 6 |
| Jan ’25 | US$144.01 | US$169.80 +17.9% | 9.9% | US$192.00 | US$140.00 | n/a | 5 |
| Dec ’24 | US$127.63 | US$169.80 +33.0% | 9.9% | US$192.00 | US$140.00 | n/a | 5 |
| Nov ’24 | US$125.32 | US$169.20 +35.0% | 9.2% | US$187.00 | US$140.00 | US$121.69 | 5 |
| Oct ’24 | US$134.34 | US$170.20 +26.7% | 8.1% | US$187.00 | US$145.00 | US$131.15 | 5 |
| Sep ’24 | US$140.73 | US$169.50 +20.4% | 9.0% | US$187.00 | US$145.00 | US$128.84 | 4 |
| Aug ’24 | US$148.49 | US$170.50 +14.8% | 8.0% | US$187.00 | US$149.00 | US$137.38 | 4 |
| Jul ’24 | US$135.23 | US$169.50 +25.3% | 8.0% | US$187.00 | US$149.00 | US$115.24 | 4 |
| Jun ’24 | US$127.10 | US$169.50 +33.4% | 8.0% | US$187.00 | US$149.00 | US$119.78 | 4 |
| May ’24 | US$151.56 | US$171.50 +13.2% | 8.2% | US$187.00 | US$149.00 | US$115.64 | 4 |
| Apr ’24 | US$142.24 | US$155.00 +9.0% | 13.5% | US$172.00 | US$120.00 | US$138.31 | 4 |
| Mar ’24 | US$131.34 | US$139.00 +5.8% | 11.9% | US$160.00 | US$120.00 | US$145.60 | 4 |
| Feb ’24 | US$120.01 | US$121.25 +1.0% | 8.4% | US$130.00 | US$104.00 | US$143.53 | 4 |
| Jan ’24 | US$96.52 | US$108.50 +12.4% | 13.7% | US$125.00 | US$85.00 | US$144.01 | 4 |
| Dec ’23 | US$96.44 | US$105.50 +9.4% | 13.5% | US$125.00 | US$85.00 | US$127.63 | 4 |
| Nov ’23 | US$81.92 | US$99.75 +21.8% | 17.0% | US$125.00 | US$78.00 | US$125.32 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Ascend Wellness Holdings
US$106.1m
Engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States.
AAWH
US$0.47
7D
-22.5%
1Y
-59.2%
Kimberly-Clark
US$44.7b
Manufactures and markets personal care and consumer tissue products in the United States.
KMB
US$134.08
7D
0.4%
1Y
10.6%
Beauty Health
US$222.2m
Designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide.
SKIN
US$1.53
7D
-6.1%
1Y
-32.3%